KRAS oncogene in non-small cell lung cancer: clinical perspectives on the treatment of an old target

M Román, I Baraibar, I López, E Nadal, C Rolfo… - Molecular cancer, 2018 - Springer
Lung neoplasms are the leading cause of death by cancer worldwide. Non-small cell lung
cancer (NSCLC) constitutes more than 80% of all lung malignancies and the majority of …

The improbable targeted therapy: KRAS as an emerging target in non-small cell lung cancer (NSCLC)

R Salgia, R Pharaon, I Mambetsariev, A Nam… - Cell Reports …, 2021 - cell.com
KRAS is a frequent oncogenic driver in solid tumors, including non-small cell lung cancer
(NSCLC). It was previously thought to be an" undruggable" target due to the lack of deep …

Immune resistance in lung adenocarcinoma

M Spella, GT Stathopoulos - Cancers, 2021 - mdpi.com
Simple Summary Lung adenocarcinoma (LUAD) is the major subtype of lung cancer and
represents the deadliest human cancer, affecting current-, ex-, and even non-smokers …

Oncogenic KRAS blockade therapy: renewed enthusiasm and persistent challenges

D Tang, G Kroemer, R Kang - Molecular cancer, 2021 - Springer
Across a broad range of human cancers, gain-of-function mutations in RAS genes (HRAS,
NRAS, and KRAS) lead to constitutive activity of oncoproteins responsible for tumorigenesis …

KRAS oncogenic signaling extends beyond cancer cells to orchestrate the microenvironment

P Dias Carvalho, CF Guimaraes, AP Cardoso… - Cancer research, 2018 - AACR
KRAS is one of the most frequently mutated oncogenes in cancer, being a potent initiator of
tumorigenesis, a strong inductor of malignancy, and a predictive biomarker of response to …

Current therapy of KRAS-mutant lung cancer

A Ghimessy, P Radeczky, V Laszlo, B Hegedus… - Cancer and Metastasis …, 2020 - Springer
KRAS mutations are the most frequent gain-of-function alterations in patients with lung
adenocarcinoma (LADC) in the Western world. Although they have been identified decades …

Targeting KRAS Mutant in Non-Small Cell Lung Cancer: Novel Insights Into Therapeutic Strategies

AL Désage, C Léonce, A Swalduz… - Frontiers in …, 2022 - frontiersin.org
Although KRAS-activating mutations represent the most common oncogenic driver in non-
small cell lung cancer (NSCLC), various attempts to inhibit KRAS failed in the past decade …

The potential utility of re-mining results of somatic mutation testing: KRAS status in lung adenocarcinoma

A Biernacka, PD Tsongalis, JD Peterson, FB de Abreu… - Cancer genetics, 2016 - Elsevier
KRAS mutant non-small cell lung cancers (NSCLCs) vary in clinical outcome depending on
which specific KRAS mutation is present. Shorter progression free survival has been …

[HTML][HTML] Clinical validation of Guardant360 CDx as a blood-based companion diagnostic for sotorasib

JM Bauml, BT Li, V Velcheti, R Govindan… - Lung cancer, 2022 - Elsevier
Objectives Effective therapy for non–small-cell lung cancer (NSCLC) depends on
morphological and genomic classification, with comprehensive screening for guideline …

ADAM 17 selectively activates the IL‐6 trans‐signaling/ERK MAPK axis in KRAS‐addicted lung cancer

MI Saad, S Alhayyani, L McLeod, L Yu… - EMBO molecular …, 2019 - embopress.org
Oncogenic KRAS mutations are major drivers of lung adenocarcinoma (LAC), yet the direct
therapeutic targeting of KRAS has been problematic. Here, we reveal an obligate …